FDA OKs Stem Cell Therapy to Reduce Infection Risk

The agency called the approval of omidubicel "an important advance" for patients with blood cancer who are undergoing allogeneic umbilical cord blood stem cell transplants.
FDA Approvals

source https://www.medscape.com/viewarticle/990896?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors